Amanda Megan Cole : Citation Profile


Are you Amanda Megan Cole?

Office of Health Economics

3

H index

0

i10 index

29

Citations

RESEARCH PRODUCTION:

4

Articles

19

Papers

RESEARCH ACTIVITY:

   6 years (2014 - 2020). See details.
   Cites by year: 4
   Journals where Amanda Megan Cole has often published
   Relations with other researchers
   Recent citing documents: 9.    Total self citations: 5 (14.71 %)

MORE DETAILS IN:
ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pco941
   Updated: 2021-11-28    RAS profile: 2020-10-01    
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers


Works with:

Devlin, Nancy (5)

Lorgelly, Paula (4)

Zamora Talaya, Bernarda (4)

Hampson, Grace (3)

Cubi-Molla, Patricia (2)

Towse, Adrian (2)

Authors registered in RePEc who have co-authored more than one work in the last five years with Amanda Megan Cole.

Is cited by:

LEVAGGI, ROSELLA (2)

Devlin, Nancy (2)

Viney, Rosalie (2)

Shah, Koonal (2)

Pertile, Paolo (2)

Garau, Martina (1)

Lorgelly, Paula (1)

Tsuchiya, Aki (1)

Cubi-Molla, Patricia (1)

Towse, Adrian (1)

Neri, Margherita (1)

Cites to:

Shah, Koonal (6)

Towse, Adrian (5)

Devlin, Nancy (4)

Tsuchiya, Aki (3)

Brazier, John (2)

Zamora Talaya, Bernarda (2)

Claxton, Karl (2)

Hole, Arne (2)

Feng, Yan (1)

Viney, Rosalie (1)

Sculpher, Mark (1)

Main data


Where Amanda Megan Cole has published?


Journals with more than one article published# docs
Applied Health Economics and Health Policy2

Working Papers Series with more than one paper published# docs
Consulting Reports / Office of Health Economics10
Research Papers / Office of Health Economics5
Briefings / Office of Health Economics4

Recent works citing Amanda Megan Cole (2021 and 2020)


YearTitle of citing document
2020Complexity Stage Model of the Medical Device Development Based on Economic Evaluation—MedDee. (2020). Peter, Luka ; Mareova, Petra ; Kua, Kamil ; Klimova, Blanka ; Mohelska, Hana ; Augustnek, Martin ; Penhaker, Marek ; Ren, Luka ; Honegr, Jan. In: Sustainability. RePEc:gam:jsusta:v:12:y:2020:i:5:p:1755-:d:325509.

Full description at Econpapers || Download paper

2020Price Models for Multi-indication Drugs: A Systematic Review. (2020). Trapero-Bertran, Marta ; Segu-Tolsa, Jose Luis ; Puig-Junoy, Jaume ; Campillo-Artero, Carlos. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:18:y:2020:i:1:d:10.1007_s40258-019-00517-z.

Full description at Econpapers || Download paper

2020Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab. (2020). Simoens, Steven ; Rothe, Celia C ; Ermisch, Michael ; Bochenek, Tomasz ; Vella-Bonanno, Patricia ; Selke, Gisbert ; Nadal, Cristina ; Campbell, Stephen ; Obach, Merce ; Nachtnebel, Anna ; Torrent-Farnell, Josep ; Mueller, Tanja ; Zara, Corinne ; Godman, Brian ; Martin, Antony P ; Pontes, Caridad ; Malmstrom, Rickard E ; Timoney, Angela ; Furst, Jurij ; Gulbinovic, Jolanta ; Bennie, Marion ; Hauegen, Renata Curi ; Mardare, Ileana. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:18:y:2020:i:1:d:10.1007_s40258-019-00527-x.

Full description at2020

Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition. (2020). Pertile, Paolo ; LEVAGGI, ROSELLA. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:18:y:2020:i:3:d:10.1007_s40258-019-00541-z.

Full description at Econpapers || Download paper

2021The economics of alternative payment models for pharmaceuticals. (2021). Goldman, Dana P ; Yu, Jeffrey C ; Hlavka, Jakub P ; Lakdawalla, Darius N. In: The European Journal of Health Economics. RePEc:spr:eujhec:v:22:y:2021:i:4:d:10.1007_s10198-021-01274-4.

Full description at Econpapers || Download paper

2020Integrative Review of Managed Entry Agreements: Chances and Limitations. (2020). Pomorski, Maciej ; Vassalo, Carlos ; Azevedo, Pamela Santos ; Guerra-Junior, Augusto Afonso ; Lipinska, Aneta ; Hauegen, Renata Curi ; Gargano, Ludmila Peres ; Alvares-Teodoro, Juliana ; Gulbinovic, Jolanta ; Pippo, Tomas ; Godman, Brian ; de Assis, Francisco ; Kwon, Hye-Young ; Iunes, Roberto ; Dias, Carolina Zampirolli ; Araujo, Vania Eloisa ; Garattini, Livio ; Zuppo, Isabella Figueiredo ; Selke, Gisbert W ; Borin, Marcus Carvalho ; Canuto, Vania Cristina ; Voncina, Luka ; Pereira, Andre Luiz ; Ortiz, Carla Hernandez ; Gomez, Carolina ; Ribeiro-Junior, Nelio Gomes ; Gambogi, Rosana ; Marquez, Sergio ; Neiva, Lais Lessa ; Furst, Jurij ; Simoens, Steven ; Cazarim, Maurilio Souza ; McClure,
2021A reply to “Who would benefit from average value?based pricing?”. (2021). Pertile, Paolo ; Levaggi, Rosella. In: Health Economics. RePEc:wly:hlthec:v:30:y:2021:i:9:p:2284-2286.

Full description at Econpapers || Download paper

2020Price Models for Multi-indication Drugs: A Systematic Review. (2020). Trapero-Bertran, Marta ; Segu-Tolsa, Jose Luis ; Puig-Junoy, Jaume ; Campillo-Artero, Carlos. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:18:y:2020:i:1:d:10.1007_s40258-019-00517-z.

Full description at Econpapers || Download paper

2020Outcome-Based Payment Schemes: What Outcomes Do Patients with Cancer Value?. (2020). Cole, Amanda ; Sussex, Jon ; Sim, Duncan ; Cubi-Molla, Patricia ; Pollard, Jack ; Lorgelly, Paula. In: The Patient: Patient-Centered Outcomes Research. RePEc:spr:patien:v:13:y:2020:i:5:d:10.1007_s40271-020-00430-x.

Full description at Econpapers || Download paper

Works by Amanda Megan Cole:


YearTitleTypeCited
2016How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes? In: Briefings.
[Full Text][Citation analysis]
paper0
2016New Age Decision Making in HTA: Is It Applicable in Asia? In: Briefings.
[Full Text][Citation analysis]
paper0
2019Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication? In: Briefings.
[Full Text][Citation analysis]
paper0
2019Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación? In: Briefings.
[Full Text][Citation analysis]
paper0
2015Do Respondents Completing Abstract, Hypothetical Priority-setting Exercises Agree With the Policy Implications of Their Choices? In: Consulting Reports.
[Full Text][Citation analysis]
paper3
2015Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK In: Consulting Reports.
[Full Text][Citation analysis]
paper1
2015Data Governance Arrangements for Real-World Evidence In: Consulting Reports.
[Full Text][Citation analysis]
paper1
2016Improving Efficiency and Resource Allocation in Future Cancer Care In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2017Data Governance Arrangements for Real-World Evidence: South Korea In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2018Barriers to Uptake of Minimal Access Surgery in the United Kingdom In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2018The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries In: Consulting Reports.
[Full Text][Citation analysis]
paper4
2018Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation In: Consulting Reports.
[Full Text][Citation analysis]
paper1
2020Indication-Based Pricing (IBP) Consultation Report In: Consulting Reports.
[Full Text][Citation analysis]
paper1
2020NICE Optimised Decisions: What is the Recommended Level of Patient Access? In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2016A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications In: Research Papers.
[Full Text][Citation analysis]
paper3
2016An Analysis of NICE Technology Appraisal Decisions Recommended in Line with Clinical Practice In: Research Papers.
[Full Text][Citation analysis]
paper0
2018Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals In: Research Papers.
[Full Text][Citation analysis]
paper5
2019Making Outcome-Based Payment a Reality in the NHS In: Research Papers.
[Full Text][Citation analysis]
paper3
2019Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates In: Research Papers.
[Full Text][Citation analysis]
paper0
2014Are the UK Systems of Innovation and Evaluation of Medical Devices Compatible? The Role of NICE’s Medical Technologies Evaluation Programme (MTEP) In: Applied Health Economics and Health Policy.
[Full Text][Citation analysis]
article0
2017A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact? In: Applied Health Economics and Health Policy.
[Full Text][Citation analysis]
article3
2018Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experiment In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article4
2020Outcome-Based Payment Schemes: What Outcomes Do Patients with Cancer Value? In: The Patient: Patient-Centered Outcomes Research.
[Full Text][Citation analysis]
article0

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated March, 2 2021. Contact: CitEc Team